From the FDA Drug Label
In standard biological assays in mice and rabbits, one unit of Insulin Aspart has the same glucose-lowering effect as one unit of regular human insulin.
The amount of blood sugar reduction per unit of insulin aspart is not explicitly stated in the provided drug labels. However, it is mentioned that one unit of Insulin Aspart has the same glucose-lowering effect as one unit of regular human insulin.
- Key point: The glucose-lowering effect of insulin aspart is equivalent to that of regular human insulin on a unit-to-unit basis.
- Clinical decision: The exact amount of blood sugar reduction per unit of insulin aspart cannot be determined from the provided information 1, 1.
From the Research
Insulin aspart typically lowers blood sugar by approximately 1.5-2 mg/dL per unit, but this effect varies significantly between individuals, as shown in a study published in 2020 2. For most adults, a common starting estimate is that 1 unit of insulin aspart will lower blood glucose by about 50 mg/dL divided by the person's total daily insulin requirement. This means someone using 50 units of insulin daily might expect 1 unit to lower their blood sugar by about 1 mg/dL, while someone using 25 units daily might see a 2 mg/dL reduction per unit. The blood glucose-lowering effect of insulin aspart begins within 10-20 minutes, peaks at 1-3 hours, and lasts 3-5 hours total, as noted in a study from 2006 3. Many factors affect this response, including body weight, insulin resistance, physical activity, stress levels, illness, and concurrent medications. Some studies, such as one from 2017 4, have evaluated the pharmacological characteristics of faster-acting insulin aspart compared with insulin aspart, but the key point for clinical practice remains the individualization of the insulin dose based on the patient's specific needs and response. To determine your personal insulin sensitivity, work with your healthcare provider to establish and refine your specific correction factor through careful monitoring and adjustment, considering the findings from recent studies like the one published in 2020 2. Key points to consider include:
- The variability in individual response to insulin aspart
- The importance of adjusting the dose based on total daily insulin requirement
- The need for careful monitoring to establish a personal correction factor
- The impact of various factors on insulin sensitivity and glucose control, as discussed in studies such as those from 2000 5 and 2009 6.